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AIMS
This was a cohort study to evaluate whether individuals exposed to angiotensin
receptor blockers have a reduced risk of dementia compared with those
exposed to angiotensin-converting enzyme inhibitors.
METHODS
The study included new users of angiotensin receptor blockers or
angiotensin-converting enzyme inhibitors (from 1995 to 2010) from UK primary
care practices contributing to the Clinical Research Practice Datalink. The
association between exposure to angiotensin receptor blockers and the risk of
incident dementia was analysed using a Cox model, adjusting for age, sex, body
mass index, diabetes, hypertension, heart failure, statin use, socioeconomic
status, alcohol, smoking, number of consultations and calendar year.
RESULTS
A total of 426 089 persons were included in the primary analysis, with 45 541
persons exposed to angiotensin receptor blockers and the remainder to
angiotensin-converting enzyme inhibitors. The total number of new diagnoses
of dementia was 6517. There was weak evidence of a decreased risk of
dementia with exposure to angiotensin receptor blockers, with follow-up
beginning at 1 year after the start of treatment (adjusted hazard ratio 0.92, 95%
confidence interval 0.85–1.00). An analysis restricted to the first 12 months after
the index date showed a larger effect on dementia risk (adjusted hazard ratio
0.60, 95% confidence interval 0.50–0.72).
CONCLUSIONS
A small reduction in dementia risk was seen with angiotensin receptor blockers
in comparison to angiotensin-converting enzyme inhibitors. However, the
strongest association was seen in early follow-up, suggesting that the inverse
association is unlikely to be causal, but instead reflects other important but
unmeasured differences between angiotensin receptor blocker and
angiotensin-converting enzyme inhibitor users.
WHAT IS ALREADY KNOWN ABOUT
THIS SUBJECT
• Experimental studies suggest that
treatments targeting the renin–angiotensin
pathway could modify the risk of dementia.
• Two observational studies indicate that
exposure to angiotensin II receptor blockers
is associated with a decreased risk of
dementia when compared with
angiotensin-converting enzyme inhibitors.
However, data from a large randomized
clinical trial were inconclusive.
WHAT THIS STUDY ADDS
• There was limited evidence of an inverse
association between exposure to
angiotensin receptor blockers and the risk
of dementia, with greater risk reduction in
the first year of follow-up. This is unlikely to
represent a causal association, as any
beneficial drug effect is unlikely to operate
on such a short time scale.
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Introduction
Dementia is characterized by a progressive decline in intel-
lect, including memory, learning, orientation, language,
comprehension and judgement [1]. It is a major public
health problem, with ∼36 million people worldwide esti-
mated to be living with dementia, and the numbers are
projected to double every 20 years [1]. The key risk factor
for most types of dementia is advanced age, although
cardiovascular risk factors, such as diabetes mellitus,
hypercholesterolaemia and hypertension in mid-life, also
contribute [2–6]. Thus, the modification of these risk
factors may prevent or delay the onset of dementia.
The renin–angiotensin system (RAS) is a hormone
system that regulates blood volume and systemic vascular
resistance, which in turn controls cardiac output and arte-
rial pressure. Experimental studies suggest that treatments
targeting this pathway, such as angiotensin-converting
enzyme inhibitors (ACEIs) and angiotensin II type 1 recep-
tor blockers (ARBs), may have beneficial effects against the
development or progression of cognitive decline and
dementia [7]. However, there are also some indications
from animal studies that long-term treatment with ACEIs
may have paradoxical neurotoxic effects [8, 9], and
ARBs may have greater neuroprotective effect than ACEIs
through prevention of vascular damage induced by
β-amyloid [10].
Clinical data comparing the effects of ARBs and ACEIs
on dementia outcomes are limited. Two observational
studies indicated that ARB exposure is associated with a
reduced incidence of dementia when compared with
ACEIs or other cardiovascular drugs [11, 12]. However, a
blinded randomized clinical trial with telmisartan (ARB)
and ramipril (ACEI) found no difference between the treat-
ments for dementia and cognitive outcomes [13].
We used real-world data from the UK Clinical Practice
Research Datalink (CPRD) to assess the overall risk of
dementia associatedwith the use of ARBs in comparison to
ACEIs. Our hypothesis was that those exposed to ARBs
have a reduced risk of developing dementia compared
with those exposed to ACEIs.
Methods
The Clinical Practice Research Datalink
The CPRD is a clinical database containing records from
computer systems used by general practitioners (GPs) to
record all clinical information [14, 15]. The database com-
prises anonymized computerized medical records from
GPs in the UK, covering ∼8% of the UK population. The
data recorded in the CPRD include demographic informa-
tion, prescription details, clinical events, preventive care
provided and information from secondary care settings.
CPRD data collection started in 1987; there are ∼5 million
patients currently registered, and 12 million patient
records in total. Diagnostic accuracy for dementia
recorded in the CPRD has been previously validated,
where 90% of the people recorded as having dementia
or Alzheimer’s disease were found to have well-
documented progressive dementia on detailed review of
the records [16].
Study participants
Data on all patients aged ≥18 years with a first recorded
prescription for an ACEI or ARB in the years 1995–2010
inclusive and dated at least 6 months after their registra-
tion date within the CPRD were retrieved. The 6 month
period ensures that the majority of those included will be
new users, and excludes prevalent users with unknown
previous duration of therapy. Angiotensin-converting
enzyme inhibitors were defined as all drugs classified in
the British National Formulary (BNF) under Chapter 2.5.5.1,
and ARBs as all drugs classified under BNF Chapter
2.5.5.2.12 [17] (see Tables S1 and S2). In order to prevent
pre-existing, undiagnosed dementia from affecting our
results, the initial 12 months of person-time following the
first ARB or ACEI prescription were excluded, so individuals
developing dementia or ending follow-up during this
period did not contribute to our main analyses. Individuals
switching from ACEI to ARB therapy or from ARB to ACEI
therapy during follow-up were censored at the date of
switching, as there have been suggestions that the protec-
tive affects of ARBs and ACEIs may persist for years after
stopping treatment [18, 19] (see Figure 1). A separate
exploratory analysis was planned to examine the potential
synergistic effect of combined ACEI and ARB treatment on
the risk of dementia for individuals who were started on
the combination treatment. However, only 193 individuals
were started on the combination and so this analysis was
not feasible and these individuals were excluded from the
study. There are also recent papers suggesting that the
combination is not advantageous and may be hazardous,
at least in diabetic patients [20–22].
Individuals with records of dementia (all aetiologies) or
cognitive impairment prior to the index date were
excluded from the study. Individuals with a record of pre-
existing dementia recorded after the index date (e.g.
history of dementia, dementia annual review) without a
record of when dementia was first diagnosed were also
excluded from the study, as dementia may be prevalent at
the start of ARB or ACEI therapy for these individuals.
Drug exposure and outcomes data
We used ever exposure to ARBs (hereafter ‘ever ARB’) vs.
never exposure to ARB (i.e. ACEI treatment only) as the
main exposure variable, based on CPRD prescriptions data.
All prescriptions for an ARB or ACEI were retrieved, and the
length of each prescription was calculated based on the
recorded number of tablets prescribed and the daily dose;
where these data were not available, the median value (28
days) was assumed.
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The outcomes of interest in this study were new diag-
noses of dementia as recorded by Read Codes (see
Tables S3–S5), but we excluded specific causes of demen-
tia, which are secondary to other medical conditions and
where ARBs are not expected to have any potential effect
(e.g. dementia due to neoplastic disease, dementia in
Creutzfeldt–Jakob disease).
Statistical methods
Follow-up time began at the end of the 12 month quali-
fying period following the first prescription of either an
ACEI or ARB (the index date) and ended at the earliest of
the following: an incident dementia diagnosis; death;
transfer out of the CPRD practice network; last data col-
lection date for the practice; or date of treatment switch
between ARB and ACEI. Otherwise, subjects remained
assigned to their treatment group even if the respective
treatments were stopped. Crude hazard ratios for ever
exposure to ARBs vs. never exposure to ARB (i.e. ACEI
treatment only) were calculated using Cox regression
models for the outcome. Cox models were then adjusted
for the following potential confounders, evaluated at the
index date: age at first prescription for ARB or ACEI (18–
54, 55–64, 65–74, ≥75 years), sex, body mass index
(BMI) category (underweight, normal, overweight/obese),
smoking status (nonsmoker, current smoker, ex-smoker),
alcohol status (nondrinker, ex-drinker or current drinker,
which was further classified as light, moderate, heavy,
unknown), diabetes status (categorized as no evidence of
diabetes, diabetes without metformin or insulin use, dia-
betes with metformin but no insulin use or diabetes with
any insulin use), hypertension (based on a recording
of diagnosed hypertension or blood pressure >140/
90 mmHg), heart failure, statin use, socioeconomic status
(assigned based on postcode-linkage and divided into
five categories with class 1 being least socially deprived
and class 5 most socially deprived), number of consulta-
tions in the preceding 6 months (≤2, 3–5, 6–9, 10–14, ≥15)
and calendar year (1995–1999, 2000–2004, 2005–2010).
Attained age (<60, 60–69, 70–79, ≥80 years) was also
included as a time-updated covariate, because age is an
important determinant of the risk of dementia.
As there is some evidence that the age at which anti-
hypertensive treatment is initiated may have a different
effect on the subsequent risk of dementia [23], a potential
interaction between age at index date was investigated by
ACEI treatment throughout 
ACEI treatment 
 
First 12 months excluded 
Ever used ARB 0 
ARB treatment throughout 
ARB treatment 
 
First 12 months excluded 
Ever used ARB 1 
ACEI treatment, switching to ARB 
ACEI treatment
First 12 months excluded 
Ever used ARB 0
ARB treatment, then stopped treatment (no switch) 
ARB treatment
(not switched to ACE inhibitor) 
 
First 12 months excluded 
Ever used ARB 1 
Stopped ARB treatment after 2 years  
Follow-up ended at 2 years
Switch to ARB after 2 years
Figure 1
Assignment of ever exposure to ARB and the duration of follow-up using example scenarios. Abbreviations are as follows: ACEI, angiotensin-converting
enzyme inhibitor; ARB, angiotensin receptor blocker
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adding an interaction term in the Cox regression model.
The primary analysis excluded 9.2% of individuals with
missing data on smoking, alcohol, BMI or socioeconomic
status.
Sensitivity analyses, model checking and
other analyses
A number of planned sensitivity analyses were carried out.
First, the primary analysis was repeated using attained age,
rather than time since start of treatment, as the principal
time scale, to provide the finest possible control for age.
Second, we assessed associations with ARB use in the
initial 12 months of exposure to provide further informa-
tion on whether any observed associations were likely to
represent a causal relationship; associations in the first 12
months would argue against this, because a causal effect
would be unlikely to operate on such a short time scale.
Third, we investigated the effect for a subset of individuals
who received repeated prescriptions for ARBs and ACEIs
for at least 1 year, because this would represent a subset of
individuals who are likely to bemore compliant with treat-
ment. Fourth, for those individuals who stopped ARB or
ACEI treatment but continued to have follow-up data after
drug discontinuation, a sensitivity analysis censoring the
follow-up 3 months after the last dose of ARB or ACEI was
also conducted. In order to ascertain the likelihood of the
direction of bias with the exclusion of individuals with
missing data from the primary analysis, the available infor-
mation on these individuals was compared with those
individuals who had complete data, including the crude
event rates with respect to the exposure status. Finally, the
proportional hazards assumptionwas tested by evaluation
of whether the estimated hazard ratio changes with time
by splitting the time since starting treatment into a
number of categories (>1 to ≤3, >3 to ≤5, >5 to ≤7, >7 years)
for the ARB-exposure variable and other covariates
included in the Cox model. Where there was evidence of
nonproportional hazards, an interaction between the vari-
able and treatment time categories was included to verify
whether it had an effect between ARB exposure and
dementia. A post hoc analysis was also conducted to verify
whether the adjusted hazard ratio for dementia risk
with ARB exposure varied with the time since starting
treatment.
Two further post hoc exploratory analyses were con-
ducted. First, we examined the role of specific ARB drugs
(telmisartan, candesartan) that are considered to cross the
blood–brain barrier and therefore potentially have activity
on the central nervous system. For this analysis, patients
were assumed to be exposed to only a single drug within
the ARB class during follow-up, taken as the first ARB
prescribed. Those treated with centrally acting ACEIs
(captopril, fosinopril, perindopril, ramipril, trandolapril and
lisinopril) [24], taken as the first ACEI prescribed, were con-
sidered the ‘unexposed’ individuals.
The second post hoc analysis was conducted with the
additional adjustment of history of stroke prior to index
date. Although stroke is a known risk factor for dementia
[25], it was not anticipated that prior history of stroke
would have an impact on the decision to prescribe ARB or
ACEI for this cohort during the time of this study [26, 27],
hence prior history of stroke was not included in the
primary analysis defined a priori. This additional adjust-
ment for the history of stroke was included in the post hoc
analysis for the risk of dementia with ARB exposure for the
follow-up period starting 12 months after the index date
(same follow-up period as for the primary analysis) and
also in the initial 12 months after exposure to ARB or ACEI.
This study protocol was finalized prior to the start of
the study and has been approved by the London School of
Hygiene and Tropical Medicine Research Ethics Commit-
tee (application number: 011/286) and the Independent
Scientific Advisory Committee of the Medicines and
Healthcare products Regulatory Agency.
Results
Study population and baseline characteristics
Of 904 857 patients identifiedwith at least one ARB or ACEI
prescription, 469 366 were included in the study (see
Figure 2). Exclusionsweremainly due to failure tomeet the
new user criteria (<6 months between start of follow-up in
the database before first prescription; (n = 282 185), prior
history of dementia (n = 5103) and follow-up ended in the
initial 12 months after starting ARB or ACEI (n = 148 010).
The median interval from the first ever ACEI or ARB pre-
scription to the end of follow-up was 4.25 years
(interquartile range 2.51–6.65), with 190 373 persons
(40.6%) with follow-up ending at least 5 years after start of
prescription. The proportion of follow-up covered by ARB
prescription amongARB users was 0.83 and the proportion
of follow-up covered by ACEI prescription among ACEI
users was 0.80. There were a total of 7427 incident demen-
tia cases recorded after the first 12 months of initiation of
ARB or ACEI treatment. A total of 419 047 persons (89.3%)
received ACEI treatment and 50 319 persons (10.7%)
received ARB treatment.
The demographics and other baseline characteristics of
all 469 366 persons by drug exposure are summarized in
Table 1. Those beginning and remaining on ACEI therapy
were more likely to be men (ACEI 52.9%, ARB 45.0%), have
a history of diabetes (ACEI 24.4%, ARB 16.6%), heart failure
(ACEI 8.1%, ARB 3.2%) and recorded statin use at baseline
(ACEI 42.1%, ARB 33.9%), while hypertension (ACEI 94.7%,
ARB 97.6%) was more common among those who were
started on ARBs. The prescribing guidelines in use during
the time of the study would generally favour ACEI treat-
ment over ARB treatment for patients requiring blockade
of the RAS [27–29].
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There were missing data on BMI (5.7%), smoking status
(0.9%), alcohol status (6.9%) and SES (0.1%); 426 089
persons (90.8%) had complete data for all baseline
variables.
Effect of ARB ever exposure (primary analysis)
After excluding patients with missing data (n = 43 277), a
total of 426 089 persons were included in the primary
analysis comparing the risk of dementia in the ever ARB
exposed (n = 45 541) with the unexposed (n = 380 548; i.e.
those exposed to ACEI), with the observation time starting
at 1 year after the index date. The total number of recorded
events of dementia (excluding dementia secondary to
other medical conditions where ARB is not expected to
have an effect) was 6517.
The crude incidence rate of dementia was lower in the
ARB group [3.46 events per 1000 person-years, 95% confi-
dence interval (CI) 3.20–3.73] compared with the ACEI
group (3.91 events per 1000 person-years, 95% CI 3.81–
4.01), with the crude hazard ratio of 0.89 (95%CI 0.82–0.97;
see Table 2). After adjusting for potential confounders,
there was weak evidence of an inverse association
between ever ARB exposure and incident diagnosis of
dementia (adjusted hazard ratio 0.92, 95%CI 0.85–1.00, P =
0.04). Figure 3 shows the survival curve for the association
between ever ARB exposure and the risk of dementia over
treatment time. The curves appear to be furthest apart
during early follow-up and tend to come together over
time. There was little indication of an interaction between
the age at index date and ARB exposure in Cox regression
analysis (adjusted hazard ratio 0.88, 95% CI 0.35–2.21,
P = 0.43).
Sensitivity analyses
The results of the sensitivity analyses are summarized in
Table 3. When the analysis was repeated using age as the
primary time scale rather than treatment time, the esti-
mate for the hazard ratio for dementia was unchanged
(adjusted hazard ratio 0.92, 95% CI 0.85–1.00). There was
evidence that ever ARB exposure was associated with a
large reduction on the risk of dementia within the first year
of starting treatment (hazard ratio 0.60, 95% CI 0.50–0.72,
P < 0.001).
In the analysis based on a subset of patients who had
received at least 1 year of prescriptions for ARB or ACEI, a
total of 323 197 individuals remained at risk after the first
year of treatment. The estimated hazard ratio for this
subset of patients was similar (adjusted hazard ratio 0.91,
95% CI 0.83–1.00) to the results for all ever ARB exposed. In
the analysis restricted to users of centrally acting agents
only, the estimated hazard ratio suggested a greater
reduction in dementia risk (adjusted hazard ratio 0.84, 95%
CI 0.71–1.00), but this is clearly limited evidence for any
real difference given the wide confidence interval.
A sensitivity analysis censoring the follow-up period to
up to 3 months after the last dose of ARB or ACEI for indi-
viduals who stopped ARB or ACEI treatment showed
similar estimates for the hazard ratio (adjusted hazard ratio
0.91, 95% CI 0.83–0.99).
Inclusion of history of stroke as an additional covariate
(to the original model with adjustment for age at first pre-
scription for ARB or ACEI, sex, BMI category, smoking
status, alcohol status, diabetes status, hypertension, heart
failure, statin use, socioeconomic status, number of con-
sultations in the preceding 6 months, calendar year and
attained age) in a sensitivity analysis did not alter the find-
ings from the primary analysis. The adjusted hazard ratio
for dementia with additional adjustment for history of
stroke was 0.93 (95% CI 0.85–1.01) with follow-up starting
at 12 months after the index date. With the repeat analysis
of the risk of dementia with ARB exposure in the initial 12
months following the index date with the additional
Patients aged ≥18 years with an overall record of ACEI
or ARB from 1995 to 2010 inclusive (n = 904 857)
Patients excluded as <6 months between start of follow-up
in GPRD and first prescription of ACEI/ARB (n = 282 185)
Patients excluded as history of dementia prior to
ACEI/ARB use (n = 5103)*
Patients excluded as started on combined ACEI/ARB
treatment (n = 193)
Patients excluded as follow-up ended in the initial 12 months
of follow-up (n = 148 010)
Patients included in the main analyses (n = 469 366)
Figure 2
Inclusion and exclusion of study participants. Abbreviations are as in
Figure 1. *Individuals with a history of dementia (n = 5103): ACEI users =
4761 (0.84% out of a total of 563 792 ACEI users); ARB users = 339 (0.58%
out of a total of 58 684 ARB users); and ACEI+ARB users = 3 (1.53% out of
a total of 196 ACEI+ARB users)
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adjustment for stroke, the adjusted hazard ratio for
dementia was 0.61 (95% CI 0.51–0.73).
For 9.2% of the individuals with missing data for BMI,
alcohol use, smoking or socioeconomic status, the crude
incidence rate of dementia was found to be higher (6.68
events per 1000 person-years, 95% CI 6.26–7.13) when
compared with those who had complete data (3.86 events
per 1000 person-years, 95% CI 3.77–3.96). However, there
Table 1
Baseline and demographic characteristics by treatment use during follow-up in people prescribed angiotensin receptor blockers (ARBs) or angiotensin-
converting enzyme inhibitors (ACEIs)
Characteristic
All patients ACEI ARB
(n = 469 366) (n = 419 047) (n = 50 319)
Total observation time (million person-years) 1.8 1.6 0.2
Age (years)
18–54 118 902 (25.3) 105 962 (25.3) 12 940 (25.7)
55–64 116 563 (24.9) 103 708 (24.7) 12 855 (25.5)
65–74 119 809 (25.5) 106 785 (25.5) 13 024 (25.9)
≥75 114 092 (24.3) 102 592 (24.5) 11 500 (22.9)
Sex
Female 225 038 (48.0) 197 366 (47.1) 27 672 (55.0)
Male 244 328 (52.0) 221 681 (52.9) 22 647 (45.0)
Body mass index
Underweight 13 225 (2.8) 11 841 (2.8) 1 384 (2.7)
Normal 102 956 (21.9) 92 040 (22.0) 10 916 (21.7)
Overweight/obese 326 532 (69.6) 291 305 (69.5) 35 227 (70.0)
Missing 266 53 (5.7) 23 861 (5.7) 2 792 (5.6)
Smoking
No 239 130 (50.9) 210 916 (50.3) 28 214 (56.1)
Ex 138 723 (29.6) 125 255 (29.9) 13 468 (26.8)
Yes 87 232 (18.6) 78 877 (18.8) 8 355 (16.6)
Missing 4 281 (0.9) 3 999 (1.0) 282 (0.5)
Alcohol
Nondrinker 87 697 (18.7) 77 586 (18.5) 10 111 (20.1)
Ex-drinker 11 416 (2.4) 10 294 (2.5) 1 122 (2.2)
Current low 105 113 (22.4) 94 043 (22.4) 11 070 (22.0)
Current medium 8 737 (1.8) 7 777 (1.9) 960 (1.9)
Current high 7 081 (1.5) 6 413 (1.5) 668 (1.3)
Current unknown amount 219 523 (46.8) 196 519 (46.9) 23 004 (45.7)
Missing 29 799 (6.4) 26 415 (6.3) 3 384 (6.8)
Hypertension
Yes 445 801 (95.0) 396 668 (94.7) 49 133 (97.6)
Heart failure
Yes 35 353 (7.5) 33 758 (8.1) 1 595 (3.2)
Diabetes
No 358 623 (76.4) 316 640 (75.6) 41 983 (83.4)
Yes – no metformin/insulin 52 743 (11.2) 48 573 (11.6) 4 170 (8.3)
Yes – metformin 41 802 (8.9) 38 659 (9.2) 3 143 (6.3)
Yes – insulin 16 198 (3.5) 15 175 (3.6) 1 023 (2.0)
Statin use
Yes 193 360 (41.2) 176 308 (42.1) 17 052 (33.9)
Stroke
Yes 29 863 (7.0) 27 438 (7.2) 2 425 (5.3)
Socioeconomic status
1 87 140 (18.6) 77 784 (18.5) 9 356 (18.6)
2 91 303 (19.4) 81 789 (19.5) 9 514 (18.9)
3 93 057 (19.8) 82 997 (19.8) 10 060 (20.0)
4 99 072 (21.1) 87 928 (21.0) 11 144 (22.1)
5 98 580 (21.0) 88 343 (21.1) 10 237 (20.3)
Missing 214 (0.1) 206 (0.1) 8 (0.1)
Calendar year
1995–1999 60 083 (12.8) 56 185 (13.4) 3 898 (7.8)
2000–2004 185 476 (39.5) 159 405 (38.0) 26 071 (51.8)
2005–2010 223 807 (47.7) 203 457 (48.6) 20 350 (40.4)
Figures are numbers (percentages) unless stated otherwise. P Values are from χ2 test for categorical variable. Statistical tests comparing the ACEI vs. ARB groups gave strong evidence
of differing distributions (P < 0.001) of all variables in the table except body mass index (where P = 0.13).
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were differences in some of the baseline characteristics
and risk factors for dementia between the two groups of
individuals; there was a higher proportion of those aged
≥75 years (missing 40.6%, complete 22.7%), female
patients (missing 52.2%, complete 47.5%), with history of
heart failure (missing 14.4%, complete 6.8%), but a lower
proportion with a history of diabetes (missing 13.7%, com-
plete 24.6%), hypertension (missing 88.8%, complete
95.6%) and recorded use of statin at baseline (missing
28.6%, complete 42.5%) for the individuals with missing
data (see Table S6). Among those with missing data, the
crude incidence rate of dementia for ACEI users was 7.00
per 1000 person-years (95% CI 6.54–7.50) compared with
4.50 per 1000 person-years in ARB users (95%CI 3.60–5.61).
Of note, therewas amarked difference in the proportion of
individuals aged ≥75 years between ACEI and ARB users
(ACEI 41.4%, ARB 33.6%) for those with missing data, in
contrast to the individuals with complete data (ACEI
22.8%, ARB, 21.7%; see Table S7).
Model checking
Evaluation of the Cox model with the inclusion of all
covariates has shown evidence of apparent nonpro-
portional hazards for the ARB exposure variable (P = 0.02).
In a post hoc analysis, stratifying the treatment effect by
time since start of treatment has shown an adjusted
hazard ratio of 0.83 (95% CI 0.72–0.96) for the follow-up
interval of >1 to ≤3 years, 0.87 (95% CI 0.75–1.01) for >3 to
≤5 years, 1.07 (95%CI 0.90–1.29) for >5 to ≤7 years and 1.05
(95%CI 0.86–1.29) for >7 years (see Table 4). Therewas also
evidence of nonproportional hazards for the covariate of
calendar period (P = 0.03), but the inclusion of an interac-
tion between follow-up time and calendar period did not
alter the estimated association between ARB exposure and
dementia (hazard ratio 0.92, 95% CI 0.85–1.00).
Discussion
Summary of main findings
In this large cohort of new users of ACEIs or ARBs, we found
limited evidence of reduced risk of incident dementia in
users of ARBs compared with ACEIs (adjusted hazard ratio
0.92, 95% CI 0.85–1.00). A post hoc analysis has shown evi-
dence of interaction between follow-up time with ever
exposure to ARB, such that an inverse association with a
reduction in risk for dementia was found in the early
follow-up period, but not observed with longer follow-up.
A separate analysis has also shown that the risk reduction
appears greatest during the first year of treatment
(adjusted hazard ratio 0.60, 95% CI 0.50–0.72).
The findings are contrary to expectations based on
current knowledge, which suggests that ARBs may
prevent or delay the onset of dementia via remodelling of
the systemic vasculature or brain microvasculature [30,
31]. Such a mechanism would suggest that any risk reduc-
tion would be greater with a longer exposure time,
because the neuropathological changes associated with
dementia precede the clinical onset of disease by many
years [32, 33]. It is unlikely that a pharmacological agent
could reverse these chronic changes within a short period
of 1 year to produce such a dramatic clinical effect. We
therefore suggest that the inverse association between
dementia risk and exposure to ARBs is likely to be
explained by noncausal factors. Although ARBs and ACEIs
have very similar treatment indications, the possibility of
confounding by indication could not be excluded. In clini-
cal practice, most patients are usually started on an ACEI if
RAS blockade is indicated, particularly in the early years of
the study [26–28, 34]. First, there was a stronger body of
clinical evidence for ACEI compared with ARB at the time
with respect to cardiovascular mortality and morbidity.
Secondly, the generic forms for some ACEIs became avail-
able in the late 1990s [35, 36], which were therefore less
costly compared with ARBs, where generic forms for one
specific ARB became available only in 2008/2009 [37, 38].
Angiotensin receptor blockers tended to be prescribed
when an ACEI was not tolerated, most commonly due to
symptoms of ACEI-related cough [39, 40]. Comparison
of the baseline characteristics of the study population
showed a higher proportion of patients with diabetes,
heart failure and statin use in the ACEI group than the ARB
group, which is also suggestive of differences in the pre-
scribing practices, whereby people with more comor-
bidities may be prescribed ACEI preferentially. Adjustment
for these variables (diabetes, heart failure and statin use)
was included in the primary analysis, and in a post hoc
sensitivity analysis, history of stroke was included as an
0
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Figure 3
Survival curve for incident dementia in study cohorts included in the
primary analysis. Abbreviations are as in Figure 1. Cox regression model
with ever exposure to ARB, adjusted for age at first prescription, sex, body
mass index, smoking, alcohol use, diabetes, hypertension, heart failure,
statin use, socioeconomic status, calendar year, number of consultations
in the last 6 months and attained age (time-updated variable). Follow-up
started 1 year after first exposure to ARB or ACEI. , ACEI; , ARB
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additional covariate, and the estimated hazard ratios for
dementia were similar with or without the inclusion of
history of stroke, suggesting that although stroke was a
risk factor it was not a confounder. There may be residual
confounding that could explain a difference in the risk of
dementia risk observed in the first year of follow-up. For
example, some variablesmay not be quantified sufficiently
in this study, such as hypertension, which was categorized
into presence/absence of hypertension, which may not be
sufficiently granular. The binary classification of statin use
at study baseline also does not take into account the dose
of statin used and the subsequent use of statin over the
course of the study, though the effect of statin use on the
risk of dementia remains unclear [41, 42]. Indirect evidence
suggesting a noncausal association was found in the
analysis restricted to patients receiving regular prescrip-
tions for at least the first year after the index date. A causal
effect would tend to be stronger in this subgroup, but the
reduction in risk of dementia was very similar to that found
in the primary analysis, suggesting that the differences
between ARB and ACEI users are most probably due to
other factors. Given the large number of important differ-
ences in the baseline characteristics of the ARB and ACEI
users, it is therefore likely that theremay be other unmeas-
ured confounders.
An exploratory analysis with ARBs thought to have the
ability to affect the brain RAS suggests a possible larger
reduction in the risk of dementia (adjusted hazard ratio
0.84, 95% CI 0.71–1.00). However, the confidence intervals
for this estimate are wide, and thus, there is limited evi-
dence of a real difference.
Strengths and limitations
Our study included a large number of patients in a real-
world clinical setting and with relatively long follow-up
period. Approximately a quarter of the individuals
included in the study were under 55 years old, whilst past
studies on dementia have been criticized for inclusion of
patients only over the age of 60 years. Given that
neurodegenerative changes may precede clinical demen-
tia by decades, it is suggested that middle-aged patients
should also be included in studies investigating potential
preventative treatments for dementia [33, 43]. Patients
Table 3
Sensitivity and exploratory analyses: incidence rates of dementia by treatment and crude and adjusted hazard ratios in people taking angiotensin receptor
blockers or angiotensin-converting enzyme inhibitors
ARB exposure
Total number of new
diagnoses of dementia
Total person-time (×105
person-years)
Incidence rate (per 103
person-years)
Crude HR
(95% CI) P Value
Adjusted HR*
(95% CI) P Value
Start of follow-up at 12 months after first prescription (attained age as time scale)
ACEI use only 5853 14.96 3.91 (3.81–4.01) 1.0 1.0
Ever ARB use 664 1.92 3.46 (3.20–3.73) 0.92 (0.85–0.99) 0.03 0.92 (0.85–1.00)† 0.04
Start of follow-up from treatment initiation up to the initial 12 months
ACEI use only 1880 4.32 4.35 (4.16–4.55) 1.0 1.0
Ever ARB use 127 0.49 2.60 (2.19–3.10) 0.60 (0.50–0.72) <0.001 0.60 (0.50–0.72) <0.001
Start of follow-up at 12 months after first prescription (time since starting treatment as time scale)
Prescription of ARB/ACEI for at least 1 year
ACEI use only 4171 11.54 3.61 (3.51–3.73) 1.0 1.0
Ever ARB use 511 1.57 3.24 (2.97–3.53) 0.90 (0.82–0.99) 0.04 0.91 (0.83–1.00) 0.05
Follow-up ending at 3 months after last dose in those who stopped ACEI or ARB
ACEI use only 4524 12.50 3.62 (3.51–3.73) 1.0 1.0
Ever ARB use 518 1.60 3.23 (2.97–3.52) 0.88 (0.80–0.96) 0.004 0.91 (0.83–0.99) 0.03
Exploratory analysis
Centrally acting ARBs vs. ACEIs (based on first prescription)
ACEI use only 5267 13.33 3.95 (3.84–4.06) 1.0 1.0
Ever ARB use 142 0.43 3.34 (2.83–3.93) 0.85 (0.72–1.01) 0.06 0.84 (0.71–1.00) 0.04
*Adjusted for age at first prescription, sex, body mass index, smoking, alcohol use, diabetes, hypertension, heart failure, statin use, socioeconomic status, calendar year, number
of consultations in the last 6 months and attained age (time-updated variable). †Adjusted for age at first prescription, sex, body mass index, smoking, alcohol use, diabetes,
hypertension, heart failure, statin use, socioeconomic status, calendar year, number of consultations in the last 6 months and time since starting treatment (time-updated variable).
The likelihood ratio test was used for significance testing. Abbreviations are as for Table 2.
Table 4
Interaction between time since starting treatment and ever exposure to
angiotensin receptor blockers on the risk of dementia
Time after starting treatment Adjusted HR* (95% CI) P Value
>1 to ≤3 years 0.83 (0.72–0.96) 0.009
>3 to ≤5 years 0.87 (0.75–1.01) 0.06
>5 to ≤7 years 1.07 (0.90–1.29) 0.44
>7 years 1.05 (0.86–1.29) 0.48
*Adjusted for age at first prescription, sex, body mass index, smoking, alcohol use,
diabetes, hypertension, heart failure, statin use, socioeconomic status, calendar
year, number of consultations in the last 6 months and attained age (time-updated
variable). The likelihood ratio test was used for significance testing. Abbreviations
are as follows: CI, confidence interval; HR, hazard ratio.
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from the CPRD are broadly representative of the adult
population in UK. The use of routinely collected data
allowed for adjustment in the analyses for multiple impor-
tant confounders, and the diagnostic accuracy of demen-
tia recording has been shown to be high [16].
It has been suggested that ARBs may have a greater
effect on certain subtypes of dementia (e.g. Alzheimer’s
disease, vascular dementia) [12, 44], but this has not been
demonstrated consistently [11]. While we have excluded
certain conditions where dementia is secondary to other
medical conditions (e.g. neoplastic disease, human immu-
nodeficiency viral disease), we did not attempt to
subcategorize the recorded dementia outcomes further
into disease subtypes for a number of reasons. First, the
underlying pathologies for dementia can be difficult to
distinguish on clinical grounds [33, 45], and in postmortem
studies, mixed pathology for dementia was found to be
more common than ‘pure’ disease aetiology [46]. Second,
records of dementia in the CPRD data were very frequently
nonspecific (e.g. senile dementia, unspecified dementia),
and thus, the suspected disease aetiology cannot be speci-
fied accurately.
There is also the possibility of misclassification with
respect to the time of onset of dementia. Given that
dementia is of an insidious onset and there could be vari-
ability in the timing of patient presentation to the GP, it is
often difficult to determine the actual date of disease
onset. Moreover, GPs may vary in terms of the practice of
recording event dates. However, there is no reason to
suspect that there would be any systematic differences in
the practice of recording of diagnosis dates between ARB
or ACEI users, and therefore, this may not be an important
source of bias for the study.
A further limitation is that we had no direct data on
adherence to treatment. We used records of prescriptions
to define exposure, and some patients might not have
taken their drugs regularly, resulting in misclassification
and potential bias in either direction.
We included only individuals with complete data in the
primary analysis and excluded 9.2% of individuals with any
missing data. Although the crude incidence rate of demen-
tia in individuals with missing data for BMI, alcohol,
smoking or socioeconomic status was higher than for the
individuals with complete data, there was also a large dif-
ference in the proportion of individuals aged ≥75 years
(missing 40.6%, complete 22.7%) between the two groups.
While there were also other differences in the baseline risk
factors for dementia, the difference in age distribution is
likely to have a greater impact on the incidence rates,
because age is a major risk factor for dementia. There was
a larger difference in the crude incidence rates of dementia
between ACEI and ARB users for individuals with missing
data when compared with those who had complete data,
but a marked difference in the proportion of individuals
aged ≥75 years between ACEI and ARB users (ACEI 41.4%,
ARB 33.6%) was also noted for those with missing data.
There are no a priori reasons to suggest that the relation-
ship between the exposure and outcome is different
between those with complete data vs. missing data, con-
ditional on the covariates. When missingness is independ-
ent of the outcome given the covariates, any bias resulting
from complete case analysis is likely to be negligible [47].
There was evidence of nonproportionality hazards for
ARB exposure. It is, however, not statistically possible to
distinguish between nonproportionality of hazards and
unmeasured risk factors.
Comparison with other studies
There are short-term open-label studies (up to 24 weeks)
with blinded end-points, which have shown that treat-
ment with ARBs resulted in improvement of some meas-
ures of cognitive function tests, when compared with
ACEIs. In these studies, patients treated with ARBs were
found to have a greater reduction in blood pressure, which
raised a question regarding whether ARB may have a
greater neuroprotective effect than ACEI via blood-
pressure-lowering effects [48, 49].
A large randomized clinical trial, ‘The Ongoing
Telmisartan Alone and in Combination with Ramipril
Global Endpoint Trial (ONTARGET)’, investigated the effect
of a specific ARB (telmisartan), ACEI (ramipril) and the com-
bination of the two treatments on the clinical diagnosis of
dementia and cognitive test results in 25 260 patients
aged ≥55 years with established cardiovascular diseases or
diabetes over median follow-up period of 56 months [13,
18]. Telmisartan and combined telmisartan–ramipril treat-
ment resulted in greater reduction in blood pressure than
ramipril monotherapy. The study, however, provided
limited evidence that telmisartan may be superior to
ramipril (odds ratio 0.90, 95% CI 0.80–1.01) with regard to
cognitive impairment, but there was no evidence of an
effect (odds ratio 0.97, 95% CI 0.89–1.06) on cognitive
decline. Combined telmisartan and ramipril did not appear
to have an impact on cognitive impairment or decline
when compared with ramipril alone.
Two large observational studies investigated the asso-
ciation between ARBs and dementia risk, where ACEIs
were included as a comparator, but these studies excluded
middle-aged patients. One used data from the administra-
tive database of the US Veteran Affairs, with individuals
(predominantly male) aged 65 years or more with cardio-
vascular disease [11], and found that ARB use was associ-
ated with a large reduction in the incidence and
progression of Alzheimer’s disease and other forms of
dementia when compared with a selected ACEI (lisinopril;
adjusted hazard ratio for Alzheimer’s disease 0.81, 95% CI
0.68–0.96; and adjusted hazard ratio for other dementia
0.81, 95% CI 0.73–0.90). However, the analysis included the
first 12 months after initiation of drug and had a relatively
short follow-up period (maximum 4 years).
A nested case–control study using CPRD data on
patients aged ≥60 years who were ever treated with an
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antihypertensive investigated the relationship between
exposure to ARB, ACEI, other antihypertensives and
dementia risk [12]. The odd ratios for probable Alzheimer’s
disease and any dementia (combined dementia out-
comes) for the ARB groupwere 0.47 (95%CI 0.37–0.58) and
0.55 (95% CI 0.49–0.62), respectively, suggesting a dra-
matic protective effect and again raising the possibility of a
noncausal explanation. These large effects have essentially
been ruled out by the randomized data and so are likely to
be artefactual.
Conclusion and recommendations
We found limited evidence of a reduced risk of dementia
amongst ARB compared with ACEI users. The effect was
more apparent during early follow-up and diminished
over time. Based on our current understanding of the
pathology underlying the disease, it is unlikely that this
represents a causal association, and the pattern of results
seen suggests that this apparent risk reduction is
explained by other underlying differences between ARB
and ACEI users.
A randomized controlled trial may be the best study
design to evaluate this question further, because further
observational studies are likely to have similar problems
with confounding. However, any clinical trial would need
to be powered adequately and of sufficiently long dura-
tion to study dementia or cognitive outcomes as primary
end-points.
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